Related Experiment Video
Updated: May 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience
1Guy's Hospital, Department of Medical Oncology, 3rd Floor, Thomas Guy House, St Thomas Street, London, SE1 9RT, UK. James.Spicer@gstt.nhs.uk
Abstract:
A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with Oncoscience in Europe for the development of a humanized monoclonal antibody, nimotuzumab, for the potential treatment (TheraCIM and RadioTheraCIM) and diagnosis (DiaCIM) of cancers of epithelial origin, such as breast, lung, head and neck, and pancreatic cancer. The antibody is currently undergoing phase II clinical trials.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy

